Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H22N4O5 |
| Molecular Weight | 386.4018 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(CC1=NC(=NO1)C2=NC=C(O)C=C2)C(=O)NC3=C(CCCC3)C(O)=O
InChI
InChIKey=CJHXBFSJXDUJHP-UHFFFAOYSA-N
InChI=1S/C19H22N4O5/c1-19(2,18(27)21-13-6-4-3-5-12(13)17(25)26)9-15-22-16(23-28-15)14-8-7-11(24)10-20-14/h7-8,10,24H,3-6,9H2,1-2H3,(H,21,27)(H,25,26)
Originator
Approval Year
Sample Use Guides
In preclinical experiments MK-6892 was administered to rats at doses between 1 and 100 mg/kg. Compound was administered orally. Plasma free fatty acid levels and vasodilation was monitored.
Route of Administration:
Oral
Binding to niacin receptor 2 was measured by 3H-NA competition. In these experiments Ki was found to be 4.0 nM (595 nM in 4% human serum). In the guanine nucleotide exchange (GTPγS) assays with membranes from CHO cells expressing the recombinant human GPR109A, the functional activity of GPR109A agonists was determined.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
135416394
Created by
admin on Mon Mar 31 21:04:50 GMT 2025 , Edited by admin on Mon Mar 31 21:04:50 GMT 2025
|
PRIMARY | |||
|
PH9ZB6IRW0
Created by
admin on Mon Mar 31 21:04:50 GMT 2025 , Edited by admin on Mon Mar 31 21:04:50 GMT 2025
|
PRIMARY | |||
|
917910-45-3
Created by
admin on Mon Mar 31 21:04:50 GMT 2025 , Edited by admin on Mon Mar 31 21:04:50 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
